Literature DB >> 32071146

Mouse Models of Myeloid Malignancies.

Faisal Basheer1,2,3, George Vassiliou1,2,3.   

Abstract

Mouse models of human myeloid malignancies support the detailed and focused investigation of selected driver mutations and represent powerful tools in the study of these diseases. Carefully developed murine models can closely recapitulate human myeloid malignancies in vivo, enabling the interrogation of a number of aspects of these diseases including their preclinical course, interactions with the microenvironment, effects of pharmacological agents, and the role of non-cell-autonomous factors, as well as the synergy between co-occurring mutations. Importantly, advances in gene-editing technologies, particularly CRISPR-Cas9, have opened new avenues for the development and study of genetically modified mice and also enable the direct modification of mouse and human hematopoietic cells. In this review we provide a concise overview of some of the important mouse models that have advanced our understanding of myeloid leukemogenesis with an emphasis on models relevant to clonal hematopoiesis, myelodysplastic syndromes, and acute myeloid leukemia with a normal karyotype.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Year:  2021        PMID: 32071146      PMCID: PMC7778217          DOI: 10.1101/cshperspect.a035535

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  2 in total

1.  Aged healthy mice acquire clonal hematopoiesis mutations.

Authors:  Desmond Wai Loon Chin; Tetsuichi Yoshizato; Stina Virding Culleton; Francesca Grasso; Magdalena Barbachowska; Seishi Ogawa; Sten Eirik W Jacobsen; Petter S Woll
Journal:  Blood       Date:  2022-01-27       Impact factor: 22.113

Review 2.  Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.

Authors:  Jennifer J Trowbridge; Daniel T Starczynowski
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 17.579

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.